SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced a strategic collaboration with MedPacto, a South Korean clinically staged company listed on KOSDAQ (235980). MedPacto, known for its focus on...
Chime Biologics and Korean Listed Company MedPacto Form Strategic Partnership to Accelerate Global Biologics Development and Manufacturing
Seaking AlphaSeeking Alpha / Seaking Alpha 3 hours ago 1 Views
Comments